Scarica l'app Stockscreener
31.74
4.14%
-1.37
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VKTX Giù?
Forum
Previsione
Precedente Chiudi:
$33.11
Aprire:
$33.4
Volume 24 ore:
1.86M
Relative Volume:
0.79
Capitalizzazione di mercato:
$3.69B
Reddito:
-
Utile/perdita netta:
$-472.34M
Rapporto P/E:
-7.6558
EPS:
-4.1459
Flusso di cassa netto:
$-340.33M
1 W Prestazione:
-8.77%
1M Prestazione:
-18.64%
6M Prestazione:
+9.30%
1 anno Prestazione:
-2.55%
Intervallo 1D:
$31.48
$33.75
Intervallo di 1 settimana:
$30.80
$36.12
Portata 52W:
$22.96
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
Nome
Viking Therapeutics Inc
Settore
Industria
Telefono
858-704-4660
Indirizzo
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
31.74 | 4.05B | 0 | -472.34M | -340.33M | -4.1459 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-26 | Iniziato | Wolfe Research | Peer Perform |
| 2025-10-29 | Iniziato | Canaccord Genuity | Buy |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Iniziato | Goldman | Neutral |
| 2025-02-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-07 | Iniziato | Citigroup | Neutral |
| 2024-12-02 | Iniziato | Piper Sandler | Overweight |
| 2024-11-22 | Iniziato | B. Riley Securities | Buy |
| 2024-11-04 | Reiterato | H.C. Wainwright | Buy |
| 2024-09-11 | Iniziato | JP Morgan | Overweight |
| 2024-06-27 | Iniziato | Morgan Stanley | Overweight |
| 2024-05-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Reiterato | Oppenheimer | Outperform |
| 2024-03-07 | Iniziato | Jefferies | Buy |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2023-05-31 | Ripresa | ROTH MKM | Buy |
| 2023-03-28 | Reiterato | Maxim Group | Buy |
| 2023-03-17 | Iniziato | Stifel | Buy |
| 2021-07-29 | Ripresa | BTIG Research | Buy |
| 2021-05-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Iniziato | BMO Capital Markets | Outperform |
| 2020-05-05 | Iniziato | Chardan Capital Markets | Buy |
| 2020-05-01 | Iniziato | BTIG Research | Buy |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-25 | Iniziato | Stifel | Buy |
| 2019-03-29 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Reiterato | Maxim Group | Buy |
| 2019-02-22 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-12 | Iniziato | B. Riley FBR | Buy |
| 2018-11-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-18 | Reiterato | Maxim Group | Buy |
| 2018-09-18 | Reiterato | Raymond James | Outperform |
| 2018-07-20 | Iniziato | SunTrust | Buy |
| 2018-06-28 | Iniziato | Raymond James | Outperform |
| 2018-06-01 | Reiterato | Laidlaw | Buy |
| 2018-05-31 | Reiterato | Maxim Group | Buy |
| 2018-03-26 | Ripresa | H.C. Wainwright | Buy |
| 2017-11-28 | Reiterato | Maxim Group | Buy |
| 2017-11-21 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Viking Therapeutics Inc Borsa (VKTX) Ultime notizie
Viking Therapeutics (VKTX) Q2 Earnings Preview: Market Pricing i - GuruFocus
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates? - Yahoo Finance
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance
Viking Therapeutics Inc (VKTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
VKTX|Viking Therapeutics Inc|Price:34.880|Chg%:+0.090 - TradingKey
Viking Therapeutics Inc expected to post a loss of $1.25 a shareEarnings Preview - TradingView
Insiders At Viking Therapeutics Sold US$15m In Stock, Alluding To Potential Weakness - Moomoo
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? - Stocktwits
Viking Therapeutics (NASDAQ:VKTX) Stock in Focus Ahead of Cash-Burn Scrutiny, Earnings Set for July 29 - TechStock²
VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner - Stocktwits
Viking Therapeutics, Inc. Revenue Breakdown – DUS:1VT - TradingView
Viking Therapeutics Inc (VKTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Viking Therapeutics Inc (VKTX) Cash Flow - TradingKey
TradingKey - TradingKey
Viking Therapeutics Inc (VKTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Viking Therapeutics Inc (VKTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
VKTX Stock Draws Fresh Attention Ahead Of Earnings: Wall Street Sees Over 170% Upside As GLP-1 Race Burns Hot - Stocktwits
Viking Therapeutics Inc (VKTX) Institutional Confidence - TradingKey
VKTX|Viking Therapeutics Inc|Price:34.770|Chg%:-0.620 - TradingKey
VKTX Stock Clocks Best Day In Nearly 3 Months On Obesity Pipeline Optimism, Buyout Speculation - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
Viking Therapeutics Inc (VKTX) Fundamental & Financial Data - Stocktwits
VKTX: Viking Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Viking Therapeutics (VKTX.US) will release its earnings report after market close on July 29. - 富途牛牛
Viking Therapeutics Inc (VKTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Viking Therapeutics (VKTX) Stock Could Be Overvalued On Fresh Diabetes Therapy News - Yahoo Finance
Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market - Yahoo! Finance Canada
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults - AOL.com
Viking Therapeutics adds Dorothy Gemmell to board of directors By Investing.com - Investing.com South Africa
Viking Therapeutics adds Dorothy Gemmell to board of directors - Investing.com
Press Release: Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors - Moomoo
Viking Therapeutics (VKTX) Appoints Dorothy Gemmell To Board As Commercial Focus Grows - Sahm
Viking Therapeutics to report Q2 2026 results on July 29 - scanx.trade
Viking Therapeutics to Report Financial Results for Second Quart - GuruFocus
Viking Therapeutics’ Q2 results arrive after markets close - Stock Titan
Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026 - Sahm
A New GLP-1 Challenger? Early Data Shows Viking's New Obesity Drug Tops Novo Rival - Stocktwits
(VKTX) Risk Channels and Responsive Allocation - Stock Traders Daily
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to C - GuruFocus
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm - Morningstar
Viking Therapeutics (VKTX) Stock Analysis: Biotechnology’s Hidden Gem with a 154% Potential Upside - DirectorsTalk Interviews
Viking Therapeutics Moves Closer To Challenging Ozempic With Phase 3 Trial Progress - Stocktwits
VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead - Stocktwits
Investigation into Viking Therapeutics Officers for Fiduciary Breach - Intellectia AI
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1 - The Motley Fool
VKTX Eyes Worst Week Since November As Trial Data Looms — Wall Street Still Sees 200% Upside - Stocktwits
Viking Therapeutics (NASDAQ:VKTX) stock maintains Phase 3 outlook despite 4.6% fall over the week - TechStock²
Should You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming "Yes." - The Motley Fool
Should You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming "Yes." - The Motley Fool
Viking Therapeutics Inc Azioni (VKTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Viking Therapeutics Inc Azioni (VKTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ZANTE GREG | Chief Financial Officer |
Jul 29 '26 |
Sale |
33.47 |
21,217 |
710,141 |
212,204 |
| Mancini Marianna | Chief Operating Officer |
Jul 29 '26 |
Sale |
33.47 |
18,217 |
609,636 |
422,760 |
2.44%
0.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):